Keros Therapeutics Files 8-K

TL;DR

Keros Therapeutics filed a standard 8-K on 8/28/25, updating corporate info. Nothing major.

AI Summary

Keros Therapeutics, Inc. filed an 8-K on August 28, 2025, reporting current information as required by the SEC. The filing details the company's corporate structure, including its state of incorporation (Delaware) and its principal executive offices located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts. The report also confirms the company's telephone number and its IRS Employer Identification Number.

Why It Matters

This filing serves as a public record of Keros Therapeutics' corporate information, ensuring transparency and compliance with SEC regulations for investors and the market.

Risk Assessment

Risk Level: low — This is a routine corporate filing with no new material financial or operational information disclosed.

Key Players & Entities

• Keros Therapeutics, Inc. (company) — Registrant
• August 28, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421 (address) — Principal executive offices
• 81-1173868 (ein) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto

Filing Documents

• kros-20250828.htm (8-K) — 38KB
• exhibit99182825pr.htm (EX-99.1) — 9KB
• 0001664710-25-000078.txt ( ) — 209KB
• kros-20250828.xsd (EX-101.SCH) — 2KB
• kros-20250828_def.xml (EX-101.DEF) — 17KB
• kros-20250828_lab.xml (EX-101.LAB) — 28KB
• kros-20250828_pre.xml (EX-101.PRE) — 17KB
• kros-20250828_htm.xml (XML) — 4KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 28, 2025, Keros Therapeutics, Inc. (the "Company") issued a press release announcing that Jasbir Seehra, the Company's President and Chief Executive Officer, will participate in a fireside chat presentation at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. Eastern time, and a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 28 , 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: August 28, 2025

View Full Filing

View this 8-K filing on SEC EDGAR